CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$235.23M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.24: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.59BUSDvs all stocks (USD)
Revenue (TTM)
66.09MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.77xvs all stocks
52-Week Change
-9.94%vs all stocks
Market Capitalization
1.59BUSDvs all stocks (USD)
Enterprise Value
1.52BUSDvs all stocks (USD)
Forward P/E
-7.72xvs Biotechnology peers
Price to Sales (TTM)
28.12xvs Biotechnology peers
Price to Book (MRQ)
2.58xvs Biotechnology peers
Enterprise to Revenue
23.05xvs Biotechnology peers
Enterprise to EBITDA
-3.71xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-668.07%vs Biotechnology peers
Return on Assets (TTM)
-30.14%vs Biotechnology peers
Return on Equity (TTM)
-56.34%vs Biotechnology peers
Revenue (TTM)
66.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5890USDUpdated Jul 19, 2026Quarterly Revenue Growth
-9.50%vs Biotechnology peers
Gross Profit (TTM)
-230.67MUSDvs all stocks (USD)
EBITDA (TTM)
-411.24MUSDvs all stocks (USD)
Net Income (TTM)
-394.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.50%vs Biotechnology peers
Operating Cash Flow (TTM)
-363.15MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-235.23MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
67.67MUSDFY2025 · Dec 31, 2025Operating Income
-440.99MUSDvs all stocks (USD)
Pre-tax Income
-412.69MUSDFY2025 · Dec 31, 2025Net Income
-412.69MUSDFY2025 · Dec 31, 2025EBIT
-440.99MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-424.17MUSDFY2025 · Dec 31, 2025Research & Development
388.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
119.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
29.20MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.81USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.81USDFY2025 · Dec 31, 2025Basic Shares Outstanding
108.38MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
108.38MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-412.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-358.68MUSDFY2025 · Dec 31, 2025Free Cash Flow
-359.81MUSDDerived from operating cash flow minus capital expenditure. This filing charges 15.92M of depreciation against 1.13M of capital expenditure, and its own free-cash-flow line reads -395.87M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
167.57MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-412.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
15.92MUSDFY2025 · Dec 31, 2025Stock-based Compensation
80.22MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-951.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.99MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-47.16MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.13MUSDFY2025 · Dec 31, 2025Purchase of Investments
-322.51MUSDFY2025 · Dec 31, 2025Sale of Investments
551.67MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
228.03MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
128.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
120.45MSharesUpdated Jul 19, 2026Shares Short
49.22MSharesUpdated Jul 19, 2026Short Ratio
7.30daysvs all stocks
Short % of Shares Outstanding
44.41%vs all stocks
% Held by Insiders
3.88%vs all stocks
% Held by Institutions
76.83%vs all stocks
Total Cash (MRQ)
375.99MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.69USDUpdated Jul 19, 2026Total Debt (MRQ)
80.49MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1296xvs Biotechnology peers
Current Ratio (MRQ)
6.10xvs Biotechnology peers
Book Value per Share (MRQ)
5.16USDUpdated Jul 19, 2026Total Assets
842.13MUSDvs all stocks (USD)
Total Current Assets
527.71MUSDFY2025 · Dec 31, 2025Total Liabilities
170.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
314.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
66.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
103.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
155.46MUSDFY2025 · Dec 31, 2025Other Short-term Investments
294.42MUSDFY2025 · Dec 31, 2025Accounts Receivable
9.47MUSDFY2025 · Dec 31, 2025Accounts Payable
20.25MUSDFY2025 · Dec 31, 2025Short-term Debt
26.48MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.29MUSDFY2025 · Dec 31, 2025Long-term Debt
66.85MUSDFY2025 · Dec 31, 2025Common Stock (Book)
12.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.59BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
671.39MUSDvs all stocks (USD)
52-Week Low
7.95USDUpdated Jul 19, 202652-Week High
28.25USDUpdated Jul 19, 202652-Week Change
-9.94%vs all stocks
Beta
1.77xvs all stocks
50-Day MA
14.29USDUpdated Jul 19, 2026200-Day MA
13.70USDUpdated Jul 19, 2026Avg 10-Day Volume
4.41MSharesUpdated Jul 19, 2026Avg 30-Day Volume
6.06MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.52USDUpdated Jul 19, 2026Other Income / Expense
-899.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 28.12Revenue Growth YoY: -0.10
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.10Altman Z-Score: 0.24
Financial Health
Altman Z-Score 0.24: distress zoneCritical
Altman Z-Score: 0.24
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$235.23M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -235,232,880Global P5: -219,013,500
Market cap is $1.59B, above the global median of $1.15BNotable
Market cap (USD): 1,589,340,900Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
IonQ, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ServiceNow, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Pacific Biosciences of California, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated